Open AccessOutcomes of Vagal Nerve Stimulator Implantation by Otolaryngologists
Author(s) -
Perez Angel Javier,
Dyckman Damian,
Schroeder Ashley A.,
Clenney Timothy L.
Publication year - 2011
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599811415823a65
Subject(s) - medicine , medical record , retrospective cohort study , epilepsy , cochlear implantation , nerve stimulator , otorhinolaryngology , depression (economics) , anesthesia , surgery , hearing loss , audiology , psychiatry , economics , macroeconomics
Objective A vagal nerve stimulator (VNS) is a FDA‐approved device implanted for treatment of intractable epilepsy and major depression in adults and children. Recently, otolaryngologists are becoming more involved in the implantation and care of side effects for these devices. Method A retrospective chart review was performed. Our local surgical database was searched for cases of VNS implantation during a period of 40 months. Fourteen cases performed by otolaryngologists were identified. Medical records were then reviewed for outcomes including medication reduction, seizure frequency and duration, device‐related complications, and surgical complications. Results Of the 14 cases performed by otolaryngologists over 40 months, 11 (78.6%) cases demonstrated either a decrease in medications required, seizure frequency, or duration. The most common side effect was voice alteration during device initiation. There were no early postsurgical complications. Conclusion These data provide support for the qualification of otolaryngologists for performing VNS implantation and monitoring postoperative and laryngeal side effects of the VNS.